NASDAQ:SGMO - Sangamo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 172.19 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.45
▼ -0.49 (-5.48%)

This chart shows the closing price for SGMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sangamo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGMO

Analyst Price Target is $23.00
▲ +172.19% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $29.00 and a low forecast of $16.00. The average price target represents a 172.19% upside from the last price of $8.45.

This chart shows the closing price for SGMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Sangamo Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/26/2021HC WainwrightInitiated CoverageBuy$25.00Medium
5/3/2021Royal Bank of CanadaInitiated CoverageOutperform$22.00High
3/3/2021Wells Fargo & CompanyLower Price TargetOverweight$36.00 ➝ $29.00High
1/5/2021Stifel NicolausInitiated CoverageHold$16.00N/A
12/16/2020HC WainwrightReiterated RatingBuy$25.00Low
9/8/2020Bank of AmericaInitiated CoverageBuy$20.00Low
7/7/2020SunTrust BanksInitiated CoverageBuyHigh
6/22/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $14.00Medium
6/19/2020WedbushReiterated RatingHold$11.00Medium
6/10/2020WedbushReiterated RatingHold$11.00High
3/4/2020WedbushReiterated RatingHold$10.00High
3/2/2020HC WainwrightReiterated RatingBuy$16.00High
12/23/2019HC WainwrightReiterated RatingBuy$16.00High
12/18/2019WedbushReiterated RatingHold$11.00Medium
12/11/2019WedbushReiterated RatingHold$11.00Low
12/9/2019CowenReiterated RatingBuyHigh
11/12/2019WedbushReiterated RatingHold$11.00Low
8/26/2019HC WainwrightInitiated CoverageBuy$16.00Medium
7/8/2019WedbushSet Price TargetHold$11.00Medium
6/23/2019WedbushSet Price TargetHold$11.00Medium
5/14/2019WedbushSet Price TargetHold$11.00Medium
3/10/2019WedbushSet Price TargetHold$10.00Medium
11/19/2018WedbushSet Price TargetHold$11.00Low
11/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$35.00 ➝ $11.00High
11/9/2018GuggenheimDowngradeBuy ➝ Neutral$18.00High
10/9/2018GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
8/9/2018WedbushReiterated RatingHold$10.00High
7/24/2018WedbushReiterated RatingHold$9.00Medium
7/23/2018CowenReiterated RatingBuyLow
6/20/2018Bank of AmericaInitiated CoverageBuy$24.00High
3/13/2018WedbushReiterated RatingHold$8.00Medium
2/25/2018BarclaysReiterated RatingBuy$30.00Low
2/23/2018Jefferies Financial GroupReiterated RatingBuyLow
2/12/2018WedbushReiterated RatingNeutral$6.00High
1/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
11/22/2017BarclaysInitiated CoverageOverweight$20.00N/A
11/15/2017WedbushReiterated RatingHold$6.00N/A
11/15/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$19.00N/A
10/13/2017Jefferies Financial GroupReiterated RatingBuy$18.00N/A
9/14/2017Jefferies Financial GroupReiterated RatingBuy$18.00High
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$20.00 ➝ $30.00Low
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$8.00High
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$17.00High
5/16/2017WedbushReiterated RatingNeutral$6.00 ➝ $4.00Medium
3/22/2017CowenReiterated RatingBuyHigh
3/1/2017WedbushReiterated RatingNeutral$4.00N/A
2/28/2017CowenReiterated RatingBuyN/A
2/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$5.00N/A
2/8/2017WedbushReiterated RatingNeutral$4.00N/A
1/5/2017WedbushReiterated RatingNeutral$4.00N/A
(Data available from 11/28/2016 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/29/2021
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/28/2021

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Sangamo Therapeutics logo
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.
Read More

Today's Range

Now: $8.45
Low: $8.34
High: $8.74

50 Day Range

MA: $9.17
Low: $7.98
High: $10.97

52 Week Range

Now: $8.45
Low: $7.89
High: $19.43

Volume

999,784 shs

Average Volume

1,171,549 shs

Market Capitalization

$1.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Sangamo Therapeutics?

The following equities research analysts have issued research reports on Sangamo Therapeutics in the last twelve months: HC Wainwright, Royal Bank of Canada, Stifel Nicolaus, TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for SGMO.

What is the current price target for Sangamo Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Sangamo Therapeutics in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 172.2%. Wells Fargo & Company has the highest price target set, predicting SGMO will reach $29.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $16.00 for Sangamo Therapeutics in the next year.
View the latest price targets for SGMO.

What is the current consensus analyst rating for Sangamo Therapeutics?

Sangamo Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGMO will outperform the market and that investors should add to their positions of Sangamo Therapeutics.
View the latest ratings for SGMO.

What other companies compete with Sangamo Therapeutics?

How do I contact Sangamo Therapeutics' investor relations team?

Sangamo Therapeutics' physical mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company's listed phone number is (510) 970-6000 and its investor relations email address is [email protected] The official website for Sangamo Therapeutics is www.sangamo.com.